Eamonn Hobbs Joins the Board of Directors at Cappella

Galway, Ireland, February 17, 2010 (ots/PRNewswire) - Cappella
(http://www.cappella-med.com/), Inc. (Cappella), a medical device
company developing dynamic solutions for the treatment of coronary
bifurcation disease, announced the addition of Mr. Eamonn Hobbs to
the Board of Directors ( http://www.cappella-med.eu/index.php?option=
com_content&view=article&id=181:board-of-directors&catid=4) .
According to Mr. Wolfgang Oster, MD, PhD, Chairman of the Board and
Managing Partner at PolyTechnos Venture-Partners GmbH, "Eamonn's
wealth of expertise and solid track record of success in our medical
device field makes him a formidable source of wisdom and judgement
for the road ahead of Cappella. The company's commercial programs
and global market expansion will greatly benefit from Mr Hobbs'
insights."

Mr. Eamonn Hobbs, President, CEO, & Director of Delcath Systems,
Inc. is an entrepreneurial senior executive with over 25 years of
medical device experience and demonstrated success in profitable
business creation, general management, sales and marketing and
product development. When asked to comment on his recent appointment,
Mr. Hobbs stated, "I am delighted to join Cappella's Board of
Directors and support the cause of this company which is all about
addressing a substantial unmet medical need. Whereas long
under-diagnosed and under-served, bifurcational lesions have now
attracted the much deserved attention of the medical community and I
am convinced that Cappella has put the best team on the field to
tackle the challenge. I am thrilled to work with Dr. Art Rosenthal
and our Board of Directors to deliver this technology to patients in
need."

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel
solutions for the treatment of complex Coronary Artery Disease (CAD)
and specifically bifurcation vascular disease. Cappella's initial
product, the Sideguard(R) (http://www.cappella-med.eu/index.php?optio
n=com_content&view=article&id=1&Itemid=2) Coronary Sidebranch Stent
& Delivery System offers interventional cardiologists a
straightforward, effective solution that focuses on treating the
sidebranch of diseased coronary arteries first, rather than the main
vessel. More importantly, it allows the preferred stent of choice for
the main vessel. An optimal stent design specific to the anatomy of
the sidebranch, combined with the qualities of Nitinol now provide a
dynamic solution for treating sidebranch disease. Cappella Medical
Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary
of Cappella, Inc. For more information, see:
http://www.cappella-med.com.

(Due to the length of some of the URLs in this release, it may be
necessary to copy and paste the hyperlinks into your Internet
browser's URL address field. Remove the space if one exists.)

Links: Cappella : http://www.cappella-med.com/

ots Originaltext: Cappella Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Contact: Claire Marie Gigon, Cappella Medical Devices
Limited,Tel: +41-(0)79-374-57-65, Email: cmgigon@cappella.ie